Stephen P. Raffanti, M.D.

Faculty Appointments
Professor of Medicine
M.P.H., Public Health , Vanderbilt University, Nashville, TennesseeM.D., Università di Genova, Genoa, ItalyB.A., Biochemistry, University of California, Berkeley, California
Office Address
Ste 103
345 24th Avenue North
Nashville, TN 37203
Ghiam MK, Rebeiro PF, Turner M, Rogers WB, Bebawy SS, Raffanti SP, Person AK, Pettit AC. Trends in HIV Continuum of Care Outcomes over Ten Years of Follow-Up at a Large HIV Primary Medical Home in the Southeastern United States. AIDS Res. Hum. Retroviruses [print-electronic]. 2017 Jun 6/26/2017; PMID: 28462622, DOI: 10.1089/AID.2017.0016, ISSN: 1931-8405.

Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?. J. Acquir. Immune Defic. Syndr. 2011 Aug 8/1/2011; 57(4): 305-10. PMID: 21423024, PMCID: PMC3141096, DOI: 10.1097/QAI.0b013e3182182e2d, ISSN: 1944-7884.

Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Barkanic G, Raffanti SP, Sterling TR. Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response. PLoS ONE. 2009 Sep 9/9/2009; 4(9): e6961. PMID: 19742315, PMCID: PMC2734183, DOI: 10.1371/journal.pone.0006961, ISSN: 1932-6203.

Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol [print-electronic]. 2009 Jul; 62(7): 729-37. PMID: 19108987, PMCID: PMC2747519, PII: S0895-4356(08)00257-6, DOI: 10.1016/j.jclinepi.2008.09.002, ISSN: 1878-5921.

Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J. Infect. Dis. 2009 Apr 4/1/2009; 199(7): 991-8. PMID: 19220139, PII: 10.1086/597124, DOI: 10.1086/597124, ISSN: 0022-1899.

Pettit AC, Barkanic G, Stinnette S, Rebeiro P, Blackwell R, Raffanti SP, Shepherd BE, Sterling TR. Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment. Int. J. Tuberc. Lung Dis. 2009 Mar; 13(3): 355-9. PMID: 19275796, PMCID: PMC2866056, ISSN: 1027-3719.

Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D'Aquila RT. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin. Infect. Dis. 2008 Nov 11/15/2008; 47(10): 1354-7. PMID: 18922071, PMCID: PMC2605467, DOI: 10.1086/592693, ISSN: 1537-6591.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J. Infect. Dis [print-electronic]. 2007 Oct 10/1/2007; 196(7): 1044-52. PMID: 17763327, PII: JID37806, DOI: 10.1086/520814, ISSN: 0022-1899.

Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J. Infect. Dis [print-electronic]. 2007 Feb 2/1/2007; 195(3): 425-31. PMID: 17205482, PII: JID36919, DOI: 10.1086/510536, ISSN: 0022-1899.

Raffanti SP, Schaffner W, Federspiel CF, Blackwell RB, Ching OA, Kühne FW. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection. 1998 Jul; 26(4): 202-7. PMID: 9717676, ISSN: 0300-8126.

Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin. Infect. Dis. 1994 Mar; 18(3): 339-47. PMID: 8011813, ISSN: 1058-4838.